title: Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial.
authors.forename: Robert
authors.initials: R
authors.lastname: Bissonnette
authors.forename: Genhui
authors.initials: G
authors.lastname: Chen
authors.forename: Chantal
authors.initials: C
authors.lastname: Bolduc
authors.forename: Catherine
authors.initials: C
authors.lastname: Maari
authors.forename: Michael
authors.initials: M
authors.lastname: Lyle
authors.forename: Liren
authors.initials: L
authors.lastname: Tang
authors.forename: John
authors.initials: J
authors.lastname: Webster
authors.forename: Youwen
authors.initials: Y
authors.lastname: Zhou
mesh_terms: D000287:Administration, Topical; D000328:Adult; D001555:Benzene Derivatives / Q000008:administration & dosage / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000473:pathology; D004311:Double-Blind Method; D004337:Drug Carriers; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D016896:Treatment Outcome
chemical_list: D001555:Benzene Derivatives; D004337:Drug Carriers; D007155:Immunologic Factors